Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

147 results about "Host immunity" patented technology

Host Defense/Innate Immunity. The immune system is composed of an innate (non-specific) and an adaptive (specific) response. Innate immunity is constitutively present and is mobilized immediately following infection. Innate immunity is termed non-specific because the protective response is the same regardless of the initiating infection.

Application of ackermann muciniphile or external vesicles thereof in preparation of drugs for treating schistosomiasis

The invention belongs to the technical field of biological medicines, and relates to application of Ackermann muciniphile or its external vesicles in preparation of a drug for treating schistosomiasis. The anti-infection immunity of a host is enhanced by adjusting intestinal flora balance (recovering diversity and composition) and improving immune response (adjusting macrophage, CD8 + T cell recruitment and Th1 / Th2 balance); meanwhile, the intestinal barrier function is improved, and pathogen invasion and inflammation are reduced; hepatic granuloma and hepatic fibrosis caused by schistosome infection are obviously relieved, and the liver function is improved; the key effect of the MIF gene in immunoregulation is disclosed, and a new direction is provided for schistosomiasis immunotherapy. Besides, the probiotics are high in treatment safety and free of obvious side effects, can be combined with chemotherapy to enhance the curative effect and reduce the side effects and drug resistance of chemical drugs, provides a lasting and comprehensive adjuvant therapy scheme for the schistosomiasis, and has important clinical application potential.
Owner:HUBEI UNIV OF MEDICINE

Application of engineered attenuated coxsackie B3 virus vector in preparation of medicine for treating traumatic craniocerebral injury

The invention belongs to the technical field of disease drugs, and particularly relates to application of an engineered attenuated coxsackie B3 virus vector (CVB3 (mu)) in preparation of drugs for treating traumatic craniocerebral injury. According to the application disclosed by the invention, after severe craniocerebral injury of a mouse, CVB3 (mu) can remodel a host immune system through single intraperitoneal injection treatment, so that the absorption speed of encephaledema on an affected side can be remarkably increased, and the effect of treating traumatic craniocerebral injury is achieved; in addition, the CVB3 (mu) has remarkable safety.
Owner:SHANTOU UNIV MEDICAL COLLEGE

Application of anti-inflammatory factor loaded recombinant attenuated coxsackie B3 virus in preparation of medicine for treating traumatic craniocerebral injury

The invention belongs to the technical field of disease drugs, and particularly relates to application of a recombinant attenuated coxsackie B3 virus loaded with an anti-inflammatory factor in preparation of drugs for treating traumatic craniocerebral injury. The virus can regulate and control a peripheral immune phenotype capable of inhibiting inflammation, after severe craniocerebral injury of a mouse, a host immune system is remodeled through single intraperitoneal injection treatment, a treatment effect is achieved in improving an immune microenvironment in the acute stage of TBI, the neuroprotective effect is observed in the early stage and the late stage of TBI, and safety is achieved.
Owner:SHANTOU UNIV MEDICAL COLLEGE

Lactobacillus salivarius combination capable of improving expression of host secretory immunoglobulin and enhancing infection resistance of host secretory immunoglobulin and metagen of lactobacillus salivarius combination

The invention discloses combined lactobacillus salivarius capable of improving expression of secreted immune globulin of a host and enhancing infection resistance of the secreted immune globulin and a metagen of the combined lactobacillus salivarius, and belongs to the technical field of microorganisms. The saliva combined lactobacillus viable bacteria and the metaplasm thereof provided by the invention have the capability of regulating and controlling host immunity to improve pathogenic bacterium infection resistance of a host oral cavity, can remarkably up-regulate expression of an oral mucosa epithelial cell substrate PIGR in vitro and in an animal body, and remarkably up-regulate expression of SIgA in the animal body, so that the host oral immunity is improved; and the compound has a huge application prospect in the aspects of regulating and controlling the oral immunity of the host, preparing products for improving the infection resistance of the oral cavity of the host and the like.
Owner:JIANGNAN UNIV

Postbiotics prepared by combining saliva with lactobacillus and capable of improving expression of host antibacterial peptide and immune globulin and application thereof

The invention discloses a metagen prepared by combining saliva with lactobacillus and capable of improving expression of host antibacterial peptide and immune globulin and application of the metagen, and belongs to the technical field of microorganisms. The combined lactobacillus salivarius disclosed by the invention has the capability of regulating and controlling host immunity and improving pathogenic bacterium infection resistance of a host oral cavity, can remarkably up-regulate expression of a human oral keratinocyte antibacterial peptide HBD-2 gene and protein in vitro, and can remarkably up-regulate expression of DEFB3 (homolog of human HBD-2) and secretory immune globulin SIgA in a mouse body; the compound can be used for preparing a series of products for enhancing the oral immunity of a host and resisting oral pathogenic bacteria infection, and has a huge application prospect.
Owner:JIANGNAN UNIV

Pseudorabies virus (PRV) expressing porcine circovirus 2 (PCV2) capsid protein on envelope and use thereof

The present disclosure provides a pseudorabies virus (PRV) expressing a porcine circovirus 2 (PCV2) capsid protein in its envelope, and use thereof. In the present disclosure, an attenuated PRV vaccine strain is used as a vector to express an exogenous immunogen. The exogenous immunogen only replaces an extracellular domain of a non-essential envelope protein of the PRV, while retaining a transmembrane domain and an intracellular domain of an original envelope protein, thereby allowing the expression of one or more exogenous immunogens on the viral envelope without changing genes of other PRV autoimmunogens. During the recombinant PRV particle being recognized by the body's immune system, the host's immune system recognizes all immunogens (exogenous immunogens and PRV autoimmunogens) on the recombinant PRV particle and then initiates an immune response, thus exerting a protective effect of a bivalent vaccine or a polyvalent vaccine based on the recombinant PRV particle.
Owner:ZHEJIANG UNIV

Cells lacking B2M surface expression and methods for allogeneic administration of such cells

Disclosed herein are cells and populations of cells comprising a genome in which the B2M gene has been edited to eliminate surface expression of MHC Class I protein in the cells or population of cells, and methods for allogeneic administration of such cells to reduce the likelihood that the cells will trigger a host immune response when the cells are administered to a subject in need of such cells.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Combination of anti-human CD39 antibody, anti-human PD-1 antibody and chemotherapy in gastric cancer

Provided herein are administration and combination therapies using a CD39 antibody, a PD-1 antibody, and FOLFOX or CAPOX in gastric cancer. The immune checkpoint inhibitor has thoroughly changed the cancer treatment normal form. These agents modulate the tumor microenvironment or other aspects of the immune system to overcome the immunosuppression of the host immune system caused by the tumor. The anti-PD-1 / programmed cell death ligand-1 (PD-L1) agents target the immunosuppressive pathway and have been shown to be beneficial in many tumor types.
Owner:TRISHULA THERAPEUTICS INC +2

Breast milk-derived staphylococcus epidermidis and application thereof

The invention discloses a breast milk-derived staphylococcus epidermidis strain and application thereof. The invention provides a staphylococcus epidermidis strain, and the preservation number of the staphylococcus epidermidis strain is CGMCC (China General Microbiological Culture Collection Center) No.31507. The staphylococcus epidermidis strain has the advantages that the staphylococcus epidermidis strain can be used for preparing the staphylococcus epidermidis strain; the strain of the staphylococcus epidermidis, provided by the invention, has good intestinal adaptive capacity, safety and stability, and can be used for inhibiting enteropathogenic bacteria and improving the immune response reaction of host immune cells.
Owner:FEIHE (AR HORQIN BANNER) DAIRY CO LTD +1

Streptococcus salivarius capable of improving expression of secreted immune globulin of host and enhancing anti-infection ability of secreted immune globulin

PendingCN118995515AImprove expression levelIncrease protein expression levelCosmetic preparationsAntimycoticsSaliva sampleStaining
The invention discloses streptococcus salivarius capable of improving expression of secreted immune globulin of a host and enhancing anti-infection capability of the host, and belongs to the technical field of microorganisms. The streptococcus salivarius is separated from saliva samples of healthy people, has the capability of regulating and controlling host immunity to improve pathogenic bacterium infection resistance of the oral cavity of a host, and is specifically reflected as follows: (1) the influence on the expression of an oral epithelial cell polymerization immunoglobulin receptor PIGR is promoted; (2) reducing the load of candida albicans in tongue tissues of the mouse; (3) promoting the expression of PIGR and SIgA in the tongue tissue of the mouse; (4) improving mouse tongue tissue HE staining pathological characterization; and (5) the invasion of Candida albicans to tongue tissues of mice is improved. Therefore, the streptococcus salivarius has a huge application prospect in products for regulating and controlling the oral immunity of the host and improving the anti-infection capability of the oral cavity of the host.
Owner:JIANGNAN UNIV

Cells lacking b2m surface expression and methods for allogeneic administration of such cells

Disclosed herein are cells and populations of cells comprising a genome in which the B2M gene has been edited to eliminate surface expression of MHC Class I protein in the cells or population of cells, and methods for allogeneic administration of such cells to reduce the likelihood that the cells will trigger a host immune response when the cells are administered to a subject in need of such cells.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Implantable acellular matrix material and preparation method thereof

The invention discloses an implantable acellular matrix material and a preparation method thereof, and belongs to the field of biomedical materials. According to the method, natural animal tissues (such as pericardium, achilles tendon or small intestine submucosa) are used as raw materials, a low-temperature chemical combined decellularization treatment technology is adopted, and the method comprises the multi-step synergistic process of pre-cooling soaking balancing, low-temperature enzymolysis, low-concentration surfactant gradient permeation cleaning, low-temperature nuclease degradation, non-crosslinking sterilization and the like. Under the condition that the treatment temperature is strictly kept at 0-8 DEG C, cell components and genetic materials (the residual DNA content is 1t, and the dry weight is 8 ng / mg) are efficiently removed, and meanwhile the natural three-dimensional fine structure of an extracellular matrix (ECM), the integrity of collagen fibrils and key bioactive components (such as glycosaminoglycans (GAGs)) are reserved to the maximum extent. The host immunological rejection reaction of the obtained material is remarkably reduced, host cell ingrowth, vascularization and tissue function reconstruction can be effectively promoted after implantation, and the material is suitable for high-end implantation scenes such as soft tissue repair and regenerative medical stents.
Owner:深圳市迈捷生命科学有限公司

Metal complex tailed with immunologically active molecules and its preparation method and application

The present invention discloses a metal complex tailed with an immunologically active molecule, as well as its preparation method and application. The metal complex tailed with an immunologically active molecule exhibits significant anticancer activity. On the one hand, the metal complex exerts cytotoxicity against rapidly growing cancer cells through its active ingredient with anti-tumor immune efficacy. On the other hand, it can also induce immunogenic cell death, enabling the host immune system to attack tumor cells and induce a tumor-specific immune response. (The metal complex of the present invention has been shown to effectively induce immunogenic cell death in non-small cell lung cancer cells and successfully activate anti-tumor immunity in mice in vaccine experiments.) Therefore, the metal complex of the present invention has outstanding effects in anti-cancer, anti-inflammatory, inducing immunogenic cell death, and achieving anti-tumor immunity, and has broad application prospects.
Owner:NANJING NORMAL UNIVERSITY

Application of FN1 in treatment of mycobacterial infection

The invention belongs to the technical field of medicines, and particularly discloses application of fibronectin 1 (FN1) in treatment of mycobacterial infection. The invention finds that the FN1 has new application, and the survival of mycobacteria can be inhibited when the FN1 is independently applied; in a mycobacterium infection model, after the FN1 protein is exogenously added, the number of mycobacteria in macrophages is remarkably reduced; on the contrary, after the FN1 is knocked down, the number of mycobacteria in the macrophage is obviously increased. Further mechanism research shows that the FN1 affects release of reactive oxygen species (ROS) and cytokines by regulating a PI3K / AKT signaling pathway, and further removes mycobacteria in macrophages. From the perspective of host immunity, the invention discloses a mechanism that FN1 affects ROS (reactive oxygen species) and inflammatory response by regulating a PI3K / AKT signal channel so as to inhibit mycobacteria, and a new medicine is provided for treatment of mycobacteria infection. On the basis, FN1 can be independently used or combined with first-line antituberculosis drugs, and a new means is provided for solving the problem of drug resistance in mycobacterium infection treatment.
Owner:CHONGQING MEDICAL UNIVERSITY

Recombinant salmonella choleraesuis nuclease regulation vector as well as construction method and application thereof

The invention discloses a recombinant salmonella choleraesuis nuclease regulation vector as well as a construction method and application thereof. After oral administration, the recombinant salmonella choleraesuis nuclease regulatory vector rSC0140 enters host immune cells, c-di-AMP is released, a host STING pathway is activated, and a broad-spectrum antiviral effect can be achieved; the recombinant strain rSC0140 is proved to be capable of activating STING pathways in macrophages and mice, causing antiviral states of the macrophages and the mice and resisting challenge of various influenza viruses; the recombinant strain has broad-spectrum antiviral efficacy and is suitable for preventing and treating various virus diseases clinically.
Owner:YANGZHOU UNIV

CD25-specific antibodies and uses thereof

The monoclonal antibody specifically binds to CD25, and the conjugate of anti-CD25 antibody are described.The CD25-specific monoclonal antibody and its conjugate do not block the binding of IL-2 to CD25, and induce little or no antibody-dependent cell-mediated cytotoxicity (ADCC).The anti-CD25 antibody and conjugate can be used, for example, to target photoimmunotherapy to T regulatory (Treg) cells in tumor beds to enhance local host immune response against tumors.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

SYSTEMS AND METHODS FOR THE DETECTION OF SEPSIS AND TREATMENT OF PATIENTS

UndeterminedES3053557R1Host responseOrgan dysfunction
Systems and methods for the detection of sepsis and treatment of patients. A sepsis detection system includes a first subsystem configured to detect the presence of an infection in a patient, a second subsystem configured to detect the presence of a dysregulated immune response in the patient, a third subsystem configured to detect organ dysfunction in the patient, a fourth subsystem configured to detect antibiotic resistance (ARB) of a pathogen in the patient, and a processing device. The first, second, third, and fourth subsystems and the processing device are communicatively coupled to each other via a network. The processing device is configured to determine the presence of sepsis in the patient based on the presence of infection, the presence of the dysregulated host response, and clinical data indicative of organ dysfunction in the patient.The subsystems utilize at least one polymerase chain reaction (PCR) procedure, Raman spectroscopy, clinical data, electronic health record (EHR) data, and antibiotic susceptibility testing (antibiogram).
Owner:DEEPULL DIAGNOSTICS SL (100 00)

Preparation method of cell sphere module biological ink and application thereof in myocardial repair material

This invention belongs to the field of biomedical engineering technology, providing a method for preparing modular bio-ink for cell spheres and its application in the field of myocardial repair therapy. First, a method for preparing stem cell spheres based on microarrays is described. By introducing a protein / polyphenol composite coating onto the cell spheres, a multifunctional armor is created, providing immune protection and immunomodulatory therapy against the host's immune system to reverse the hostile microenvironment and promote the healing process of infarcted myocardial tissue. Second, using microfluidic droplet control technology, gel microspheres loaded with bioactive substances are prepared from biocompatible biomaterials. These microspheres are then densely packed and coated to form cell sphere particle gels. These gels can be used for disease treatment via direct injection or bio-3D printing, showing promising application prospects.
Owner:DALIAN UNIV OF TECH

Triterpene alcohol ferulate compound as well as preparation method and application thereof

The invention belongs to the technical field of chemical medicines, and particularly relates to a novel triterpene alcohol ferulate compound as well as a preparation method and medical application thereof. According to the invention, oryzanol is used as a raw material, and the new triterpene alcohol ferulate compound is obtained through reversed-phase preparative high performance liquid chromatography and SFC chiral separation and purification. A method and a tool of network pharmacology are used for researching the action mechanism of potential anti-inflammatory and anti-infection related treatment of the new compound. Hierarchical analysis from a global network to a core target reveals a possible action mechanism of the compound in anti-inflammatory and anti-infection, and highlights a regulation mode of a key acting protein. Wherein IGF1R, CTSS, MMP2, BCL2 and other proteins may be core regulatory factors of compound mediated host immune regulation and bacterial drug resistance inhibition, and an important theoretical basis is provided for further research on molecular mechanisms and potential therapeutic targets of compounds in anti-inflammatory and anti-infection related treatment.
Owner:HUBEI NONGFA PHARM CO LTD +1

Method for preparing specific MHC haplotype-derived cell-binding virus

PendingCN121975744AIncrease screening positivity rateMicroorganism based processesViruses/bacteriophagesVaccine virusEmbryo
The invention relates to the fields of molecular biology and virology, and provides a method for preparing a specific MHC haplotype-derived cell-binding virus. The method comprises the following steps: firstly, obtaining chick embryos of different haplotypes, separating CEF cells, transiently expressing exogenous fluorescent protein through electrotransfection, then carrying out virus inoculation, carrying out flow sorting to obtain a fluorescent positive cell population carrying MDV, and carrying out quantitative analysis on the cell population to obtain the specific MHC haplotype chicken Marek's Disease Virus (MDV), thereby obtaining the specific MHC haplotype chicken Marek's Disease Virus Marek's Disease Virus Marek's Disease Virus Marek's Disease Virus. And carrying out in-vitro propagation to obtain the purified MDV with a specific haplotype source. The purified virus can provide a test material for related research of haplotype on virus infection, and can be widely applied to in-vitro purification of different cell binding viruses and related research of specific MHC molecule presenting virus peptides. The method disclosed by the invention is beneficial to carrying out related research aiming at the host immune response of the virus and analyzing the hereditary basis of haplotype to MDV differential resistance, and is expected to be applied to preparation of vaccine virus.
Owner:CHINA AGRI UNIV

Car for use in the treatment of hvg disease

The invention provides an optimized and far potent chimeric antigen receptor for its use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 in a recipient patient who is negative for HLA-A*02, i.e. the patient prior to transplantation does not express HLA-A*02. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02.
Owner:MEDIZINISCHE HOCHSCHULE HANNOVER +1

Engineered cell intraocular transplantation device based on hyaluronic acid scaffold

The invention discloses an engineered cell intraocular transplantation device based on a hyaluronic acid scaffold, the engineered cell intraocular transplantation device comprises a vitreous body and a cell intraocular transplantation device fixed in the vitreous body, the cell intraocular transplantation device comprises engineered cells, a hyaluronic acid hydrogel scaffold and a suture sclera; according to the engineered cell storage container of the capsule-shaped structure, a semi-permeable polymer film is adopted, the semi-permeable film is provided with gaps of 15 nm, engineered cells wrapped by hyaluronic acid hydrogel are arranged in the semi-permeable film, the bottom of the semi-permeable film is a sealed end, and a detachable sealing end cover is arranged at the top end of the semi-permeable film; the sealing end is used for preventing invasion of an eye immune system; and the sealing end cover is sealed by using a medical-grade sealant, so that the cells are prevented from being invaded by host immune cells. The invention provides a new technical solution for the field of protection and transplantation of engineered cells, and shows remarkable economical efficiency, practicability, safety, operation convenience and stability.
Owner:HENAN PROVINCIAL EYE HOSPITAL (HENAN PROVINCIAL EYE INST)

Host immune cells engineered to overexpress a FOXK1 polypeptide

T lymphocytes play a key role in the immune response and their functions are intimately linked to metabolic programs. During immune responses, T cells undergo a metabolic reprogramming notably characterized by an increased aerobic glycolysis. Using a quantitative phosphoproteomic approach, the inventors have identified a new transcription factor called Foxk1 as being highly phosphorylated in T cells upon T Cell Receptor (TCR) engagement. The results also indicate that Foxk1 phosphorylation and nuclear translocation is dependent of the AKT-mTOR kinase activities. Using T-cell specific Foxk1 deficient mice (Foxk1- / -), we demonstrated that Foxk1 is required for full T cell activation. Foxk1-deficient T cells exhibited reduced proliferation and cytokine secretion following TCR stimulation. Furthermore, T cells from Foxk1- / - mice were less prone to acquire an effector like phenotype than wild-type cells when challenged in vivo. Conversely, Foxk1 overexpression in T cells enhanced their effector functions in a TCR-dependent manner. In CD8+ T cells, this effect also results into enhanced cancer cell killing capacity in vitro, and improved tumor rejection in vivo. Altogether, these results indicated that Foxk1 is a major regulator of T cell metabolism and thus, of T cell effector functions. Thus, the present invention relates to host immune cells engineered to overexpress a Foxk1 polypeptide and their use of the treatment of cancer.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

Treatment method for sleep disease in fancy carp culture

The invention relates to the technical field of aquaculture, and discloses a treatment method for sleep diseases in fancy carp culture. According to the invention, early-stage rapid intervention is taken as a core, and in combination with the application of the improved suspension and the synergistic effect of the slow-release immune bait, the drug targeting is improved, the stress injury to fish bodies is reduced, the host immunity is enhanced, and the virus diffusion is effectively inhibited; according to the dynamic environment regulation and control technology, through real-time monitoring of water quality parameters and linkage adjustment of drug concentration and oxygenation strategies, environmental adaptability in the treatment process is ensured, drug abuse and residual pollution are reduced, and ecological balance of a water body is maintained; the cross infection of viruses is blocked by a whole-course partition management strategy, and the degradation of drug metabolites is accelerated and the treatment cycle is shortened in combination with the ecological restoration effect of the complex probiotics and the citric acid buffer agent. In addition, a treatment file database is established, the scheme is continuously improved through historical case analysis, the cure rate and operation efficiency are improved, and the comprehensive cost is reduced.
Owner:HENAN ZHONGDING AGRICULTURAL DEVELOPMENT CO LTD

Application and method of RSAD2 agonist glycopyrronium in resisting RSV infection

The invention provides an application and a method of an RSAD2 agonist glycopyrronium in resisting RSV infection. The method comprises the following steps: S1, virtual screening and molecular docking; s1.1, performing virtual screening and molecular docking; s1.2, carrying out molecular dynamics simulation; s2, cell culture and RSV infection; s3, performing RT-qPCR detection on the expression of the RSAD2 and the virus load of the RSV; s4, performing Westernblot analysis on the influence of a small molecule compound on the expression of the RSAD2; s5, CCK8 is used for detecting the toxicity of the compound to Beaas-2b cells; s6, carrying out indirect immunofluorescence detection on a fluorescence signal of the RSV; s7, animal model establishment; s8, carrying out HE dyeing; s9, carrying out enzyme-linked immunosorbent assay (ELISA); and S10, statistical analysis. According to the present invention, the small molecule agonist targeting the host immune factor RSAD2 is screened, the endogenous antiviral factor is activated from the host perspective, the drug resistance problem caused by direct virus targeting is avoided, the RSAD2 is adopted as the host natural antiviral molecule, the activation strategy has good targeting property and good safety, and the efficient anti-RSV effect under the low toxic-side effect is achieved.
Owner:CENT SOUTH UNIV

Methods to enhance the effectiveness of immunotherapy and strengthen the host immune response

This invention relates to the field of appropriate immunotherapy for activating the immune response in patients. More specifically, the present invention relates to negative anti-EPO function modulators useful as active ingredients in pharmaceutical compositions for immunomodulatory strategies in therapies (e.g., cancer immunotherapy, therapies for infectious and inflammatory diseases) or for activating the immune system, enhancing cell-based or pharmacological or vaccine-based immunotherapy, and stimulating the immune system response of patients as needed. In particular, the present invention also describes how to restore the immune response in pathological conditions such as cancer and refractory infections, for example, by enhancing and ensuring therapeutic access to immunotherapy strategies by products consisting of EPO pathway inhibitors that can function as active pharmaceutical ingredients in vaccine compositions that stimulate the immune response in cancer, infectious diseases, and inflammatory diseases and be delivered to patients, thereby eliminating "tolerogenic" stimulation.
Owner:アンドレマコン エッセ·エッレ·エッレ

Peptides and antibodies for removing biofilms

To provide peptides and antibodies for removing biofilm.SOLUTION: The disclosure provides an isolated or recombinant polypeptide that is useful to vaccinate individuals suffering from a chronic / recurrent biofilm disease or as a therapeutic drug for those with an existing infection. The individual's immune system will then naturally generate an antibody which will prevent or clear these bacteria from the host by interfering with the construction and / or maintenance of a functioning and protective biofilm. Alternatively, an antibody against the polypeptide can be administered to treat or prevent infection. Bacteria released from the biofilm by the technology made by the present inventors are more readily cleared by the remainder of the host's immune system.SELECTED DRAWING: Figure 1
Owner:RES INST AT NATIONWIDE CHILDRENS HOSPITAL

Pharmaceutical compositions and methods for treating fungal infections

PCT designated stage expiredWO2025015118A1AntimycoticsFungal antigen ingredientsImmunopotencyVaccination
This invention describes pharmaceutical compositions and their methods of use utilizing inactivated F-box protein 1 deletion (fbp1Δ) mutant fungal cells and adjuvant ODN 2395. The pharmaceutical compositions can be administered by intranasal (IN) inhalation, subcutaneous (SC) injection, or intramuscular (IM) injection. Vaccination with a pharmaceutical composition confers host immunity to fungal infection in different host backgrounds and in different aged hosts.
Owner:RUTGERS THE STATE UNIV

Methods and compositions for stimulating immune response

The present invention relates to methods and compositions for stimulating an immune response. In particular, the present invention relates to immunostimulatory RNA molecules comprising sequences derived from an Influenza A virus nucleoprotein-encoding RNA molecule that act as adjuvants and / or immunostimulatory agents to enhance host immune responses.
Owner:TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIV MAINZ GEMEINNUETZIGE GMBH